Details van artikel 130 van 340 gevonden artikelen
Four-Year Survival Rate After Second Line Conversion Treatment to Hepatic Resection Using Triplet Hepatic Artery Infusion and Intravenous Cetuximab for KRAS WT Unresectable Metastatic Colorectal Cancer (European Trial Optiliv, NCT00852228)
Titel:
Four-Year Survival Rate After Second Line Conversion Treatment to Hepatic Resection Using Triplet Hepatic Artery Infusion and Intravenous Cetuximab for KRAS WT Unresectable Metastatic Colorectal Cancer (European Trial Optiliv, NCT00852228)